Conditions: Gastroesophageal Reflux Disease (GERD)
Keywords: GERD erosive GERD erosive esophagitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1069
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Detailed description:
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Rabeprazole sodium intervention 2: Esomeprazole
Intervention descriptions: intervention 1: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks. intervention 2: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.

Protocol document: